Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-07-28
2002-07-09
Tate, Christopher R. (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C424S751000
Reexamination Certificate
active
06417205
ABSTRACT:
FIELD OF THE INVENTION
The invention relates generally to the field of regulation of angiogenesis and vasculogenesis, particularly to induction of angiogenesis to promote growth of new vasculature.
BACKGROUND OF THE INVENTION
Angiogenesis and vasculogenesis are processes involved in the growth of blood vessels. Angiogenesis is the process by which new blood vessels are formed from extant capillaries, while vasculogenesis involves the growth of vessels deriving from endothelial progenitor cells. Angiogenesis and vasculogenesis, and the factors that regulate these processes, are important in embryonic development, inflammation, and wound healing, and also contribute to pathologic conditions such as tumor growth, diabetic retinopathy, rheumatoid arthritis, and chronic inflammatory diseases (see, e.g., U.S. Pat. No. 5,318,957; Yancopoulos et al. (1998)
Cell
93:661-4; Folkman et al. (1996)
Cell
87;1153-5; and Hanahan et al. (1996)
Cell
86:353-64).
Both angiogenesis and vasculogenesis involve the proliferation of endothelial cells. Endothelial cells line the walls of blood vessels; capillaries are comprised almost entirely of endothelial cells. The angiogenic process involves not only increased endothelial cell proliferation, but also comprises a cascade of additional events, including protease secretion by endothelial cells, degradation of the basement membrane, migration through the surrounding matrix, proliferation, alignment, differentiation into tube-like structures, and synthesis of a new basement membrane. Vasculogenesis involves recruitment and differentiation of mesenchymal cells into angioblasts, which then differentiation into endothelial cells which then from de novo vessels (see, e.g., Folkman et al. (1996)
Cell
87:1153-5).
Several angiogenic and/or vasculogenic agents with different properties and mechanisms of action are well known in the art. For example, acidic and basic fibroblast growth factor (FGF), transforming growth factor alpha (TGF-&agr;) and beta (TGF-&bgr;), tumor necrosis factor (TNF), platelet-derived growth factor (PDGF), vascular endothelial cell growth factor (VEGF), and angiogenin are potent and well-characterized angiogenesis-promoting agents. In addition, both nitric oxide and prostaglandin (a prostacyclin agonist) have been shown to be mediators of various angiogenic growth factors, such as VEGF and bFGF. However, the therapeutic applicability of some of these compounds, especially as systemic agents, is limited by their potent pleiotropic effects on various cell types.
Angiogenesis and vasculogenesis have been the focus of intense interest since these processes can be exploited to therapeutic advantage. Stimulation of angiogenesis and/or vasculogenesis can aid in the healing of wounds, the vascularizing of skin grafts, and the enhancement of collateral circulation where there has been vascular occlusion or stenosis (e.g., to develop a “biobypass” around an obstruction due to coronary, carotid, or peripheral arterial occlusion disease). There is an intense interest in factors that are well-tolerated by the subject, but that are of high potency in effecting stimulation of angiogenesis and/or vasculogenesis.
Related Art
Villablanca ((1998) “Nicotine stimulates DNA synthesis and proliferation in vascular endothelial cells in vitro,”
J. Appl. Physiol.
84:2089-98) studied the effects of nicotine on endothelial DNA synthesis, DNA repair, proliferation, and cytoxicity using cultures of bovine pulmonary artery endothelial cells in vitro.
The reference Carty et al. ((1996) “Nicotine and cotinine stimulate secretion of basic fibroblast growth factor and affect expression of matrix metalloproteinases in cultured human smooth muscle cells,”
J Vasc Surg
24:927-35) demonstrate that nicotine stimulates vascular smooth muscle cells to produce fibroblast growth factor, and also upregulates the expression of several matrix metalloproteinases. The investigators propose that these data demonstrate mechanisms by which smoking may cause atherosclerosis and aneurysms.
The reference by Belluardo et al. ((1998) Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the tel-and diencephalon of the rat,”
Neuroscience
83:723-40) reported that nicotine stimulates the expression of fibroblast growth factor-2 in rat brain, which the investigators propose may explain the neuroprotective effect of nicotine in the rat brain.
Moffett et al. ((“Increased tyrosine phosphorylation and novel cis-actin element mediate activation of the fibroblast growth factor-2 (FGF-2) gene by nicotinic acetylcholine receptor. New mechanism for trans-synaptic regulation of cellular development and plasticity,”
Mol Brain Res
55:293-305) report that nicotine stimulates the expression of fibroblast growth factor-2 in neural crest-derived adrenal pheochromatocytes utilizing a unique transcriptional pathway that requires tyrosine phosphorylation. The authors propose that these findings suggest that activation of nicotine receptors may be involved in neural development.
Cucina et al. ((1999) “Nicotine regulates basic fibroblastic growth factor and transforming growth factor &bgr;
1
production in endothelial cells,”
Biochem Biophys Res Commun
257:302-12) report that nicotine increases the release of bFGF, decreases the release of TGF&bgr;1 from endothelial cells, and increases endothelial mitogenesis. The authors conclude that these effects may have a key role in the development and progression of atherosclerosis.
Volm et al. (1999) “Angiogenesis and cigarette smoking in squamous cell lung carcinomas: an immunohistochemical study of 28 cases.”
Anticancer Res
19(1A):333-6 reports that angiogenesis in lung tumors is linked to a patient's smoking habits.
Macklin et al. (1998) “Human vascular endothelial cells express functional nicotinic acetylcholine receptors,”
J. Pharmacol. Exper. Therap.
287:435-9 reports that endothelical cells express both functional nicotinic (neuronal type) and muscarinic acetylcholine receptors.
U.S. Pat. Nos. 5,318,957; 5,866,561; and 5,869,037 describe use of various compounds (haptoglobin and estrogen) and methods (adenoviral-mediated gene therapy of adipocytes) to effect angiogenesis.
For recent reviews in the field of angiogenesis and vasculogenesis, see, e.g., Yancopoulos et al. (1998)
Cell
93:661-4; Folkman et al. (1996)
Cell
87;1153-5; and Hanahan et al. (1996)
Cell
86:353-64.
SUMMARY OF THE INVENTION
The present invention features methods for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial disease.
One object of the present invention to provide a method of controlling, particularly enhancing, angiogenesis, particularly with limited or no adverse effects.
Another object of the present invention is to provide a method of treating and preventing diseases and ailments involving angiogenesis such as myocardial and cerebral infarctions, mesenteric or limb ischemia, wounds, and vascular occlusion or stenosis.
Another object of this invention is to provide a method of enhancing angiogenesis to accelerate wound healing, or the vascularization of a skin graft, musculocutaneous flap or other surgically transplanted tissue; or to enhance the healing of a surgically created anastomosis.
These and other objects, advantages, and features of the invention will become apparent to those persons skilled in the art upon reading the details of the methods of the invention and compositions used therein as more fully described below.
REFERENCES:
patent: 4725609 (1988-02-01), Kull, Jr. et al.
patent: 5318957 (1994-06-01), Cid et al.
patent: 5508030 (1996-04-01), Bierman
patent: 5866561 (1999-02-01), Ungs
patent: 5869037 (1999-02-01), Crystal et al.
Kanekura, T. et al., J of Dermatology, 22(9): 709-705 Successful treatment of pyoderma gangrenosum with niotine chewing
Cooke John
Heeschen Christopher
Jang James
Tsao Phillip
Borden Paula A.
Bozicevic Field & Francis LLP.
Flood Michele C.
Francis Carol L.
Tate Christopher R.
LandOfFree
Nicotine in therapeutic angiogenesis and vasculogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nicotine in therapeutic angiogenesis and vasculogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nicotine in therapeutic angiogenesis and vasculogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2900025